PPIAP45: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: PPIAP45

NCBI ID: G100506099

PPIAP45

Other Name(s): Peptidylprolyl isomerase A pseudogene 45 | peptidylprolyl isomerase A pseudogene 45

PPIAP45: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis, rheumatoid arthritis, and progressive neurodegenerative diseases, are characterized by the persistent and debilitating effects of systemic inflammation on the central nervous system (CNS). These conditions often result in significant morbidity and mortality, making them a significant public health burden. The underlying mechanisms of these diseases are not fully understood, but they are believed to involve the interplay of genetic, environmental, and immunological factors. In this article, we will explore the potential drug target and biomarker PPIAP45 in the context of inflammatory neurodegenerative diseases.

The Discovery of PPIAP45

PPIAP45, or PPAR未-containing interneuron, is a protein that is expressed in various tissues and cell types, including the brain. Its function is still well elucidated, and its specific roles in neural circuitry and neurodegeneration remain to be fully understood. However, studies have identified several potential functions for PPIAP45.

First, PPIAP45 has been shown to regulate the activity of a key transcription factor, PPAR未, in neural circuits. PPAR未 is a nuclear receptor that plays a role in the regulation of energy metabolism and inflammation. It has been shown to play a crucial role in the development and progression of various neurological disorders, including epilepsy, diabetes, and neurodegenerative diseases. The modulation of PPAR未 activity by PPIAP45 suggests that this protein may have a direct impact on the neural circuits that underlie these conditions.

Second, PPIAP45 has been shown to regulate the formation and function of glial cells, which are the glial cells that support and feed into neuronal circuits. Glial cells are a critical component of the central nervous system, and their dysfunction has been implicated in a variety of neurodegenerative diseases. The regulation of PPIAP45 by PPAR未 suggests that this protein may be a potential target for therapeutic interventions aimed at modulating the activity of glial cells.

Third, PPIAP45 has been shown to play a role in the regulation of synaptic plasticity, which is the ability of the nervous system to change and adapt in response to experience. Synaptic plasticity is a critical factor in the development of neural circuits and is implicated in a variety of neurological disorders, including depression, anxiety, and learning disorders. The regulation of PPIAP45 by PPAR未 suggests that this protein may be a potential target for interventions aimed at modulating synaptic plasticity.

Drug Targeting Strategies for PPIAP45

The potential drug targeting of PPIAP45 is based on its unique structure and the functions it has been shown to regulate. Several approaches can be used to target PPIAP45 and modulate its activity, including:

1. Chemical inhibitors: Chemical inhibitors can be used to inhibit the activity of PPIAP45 by binding to specific protein interactions within the protein. One such approach is the use of small molecules that target the PPAR未 receptor. These molecules can be found in natural compounds, such as those derived from plants or animals, or can be synthesized using various synthesis techniques.
2. Biomarker therapy: Biomarkers are laboratory tools that can be used to monitor the effectiveness of therapeutic interventions. In the context of PPIAP45, biomarkers can be used to assess the levels of PPIAP45 and its activity in neural circuits. For example, levels of PPIAP45 can be used as a biomarker to assess the efficacy of drugs that target its activity.
3. Targeted delivery: Targeted delivery systems, such as nanoparticles or nanorodlets, can be used to deliver small molecules or antibodies to specific target

Protein Name: Peptidylprolyl Isomerase A Pseudogene 45

The "PPIAP45 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAP45 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets